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Background: Atrial ﬁbrillation (AF) is the most common sustained arrhythmia with high risk
for many cardiovascular (CV) complications. Adherence to recommended management
guidelines is important to avoid complications. In India, there is little knowledge on how
AF is managed in real world.
Methods: This is a cross-sectional study of patients in India enrolled in RealiseAF survey
between February 2010 and March 2010 with a diagnosis of AF within the last 12 months.
Results: From 15 centers, 301 patients {mean age 59.9 years (14.4); 52.5% males} were
recruited. AF was controlled in 50% of patients with 77 (26.7%) in sinus rhythm and 67
(23.3%) with heart rate <80 beats/min. Hypertension (50.8%), valvular heart disease (40.7%),
heart failure (25.9%), and diabetes (20.4%) were the most common underlying CV diseases.
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Increased risk for stroke (CHADS2 score ≥ 2) was present in 36.6%. Most of the patients (85%)
were symptomatic. AF was paroxysmal, persistent, and permanent in 28.7%, 22.7%, and
34.3% respectively. In 14%, AF was diagnosed as ﬁrst episode. Forty-six percent of patients
had rate control, 35.2% rhythm control, 0.3% both strategies, and 18.4% received no therapy
for AF before the visit. At the end of the visit, adoption to rate control strategy increased to
52.3% and patients with no therapy decreased to 7%.
Conclusion: AF in India is not adequately controlled. Concomitant CV risk factors and risk of
stroke are high. The study underscores the need for improved adoption of guideline-directed
management for optimal control of AF and reducing the risk of stroke.
# 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Atrial ﬁbrillation (AF) is the most common sustained cardiac
arrhythmia with a prevalence of 1–2% in the general popula-
tion.1,2 The prevalence of AF increases with age and, in the
elderly population, cardiovascular (CV) risk factors and co-
morbidities such as hypertension, diabetes, congestive heart
failure, coronary artery disease, valvular heart disease (VHD),
and stroke are common.3–6 As CV risk factors are important
predictors of AF, the rapidly aging population of the world
would substantially increase the prevalence of AF in the
coming years. By 2050, the number of people with AF is
projected to be 15 million in the United States.1,7 A similar
trend is projected for the European population8 too. For India,
the United Nations Populations Fund has projected a 326%
increase in the number of people aged between 60 and 80 years
by the year 2050 (from the year 2000).9 A 700% increase is
projected in the number of people above the age of 80 years.9
Though large-scale population-based studies on the preva-
lence of AF are not available in India, the projected high
increase in the aged population only warns us of the
concomitant increase in the prevalence of AF.
AF poses a high risk for complications such as thrombo-
embolism and heart failure (HF). Uncontrolled AF also leads
to frequent hospitalizations and reduced quality of life.10 To
reduce the clinical and economical burden occurring due to
complications, optimal control of AF is essential. For this,
knowledge on the prevalent practice in the management of
AF is important. The data that are available today are from
studies mainly on American or European population.11–13
The Euro Heart Survey14 which assessed the management of
AF in over 5000 ambulant and hospitalized patients reported
lack of adherence to guidelines. RECORD AF study assessed
management of paroxysmal/persistent AF in recently diag-
nosed patients.15 It was observed that the young, frequently
symptomatic and recently diagnosed patients received
rhythm control strategy, while patients with history of
HF, VHD, and persistent AF received rate control therapy.15
These data pertain to certain types of AF and do not provide
representative information on characteristics and manage-
ment of patients with the whole spectrum of AF. The
management of AF also may vary signiﬁcantly according to
different medications administered and country-speciﬁc
therapeutic strategies. There are very little data from Indiaon management practices of AF and the prevalence of CV
risk factors in this population. Small studies like CRAFT16
provide some insight on treatment of AF only in
patients with rheumatic VHD. This underscores the need
for a study on up-to-date, real-life management of patients
with AF in India.
The current study presents data on Indian patients enrolled
in the REal Life global Survey Evaluating17 patients with atrial
ﬁbrillation (RealiseAF).
The primary objectives of the study were to assess the
proportion of patients with control of AF and investigate the
CV risk proﬁle of patients with AF. Control of AF was deﬁned as
presence of sinus rhythm in patients with history of AF or a
heart rate (HR) ≤80 beats/min in patients who were in AF. The
secondary objectives were: to describe the characteristics of
the AF; describe the management of AF in terms of treatment
strategy (rate vs. rhythm control); to assess the proportion of
patients being treated with evidence-based medicine and the
proportion of patients with speciﬁc CV events/interventions
leading to hospitalization within the past 12 months. We also
aimed to assess the health-related quality of life (QoL)
associated with AF.
2. Methods
RealiseAF is an international, observational, cross-sectional
survey aimed at evaluating AF management and CV risk
proﬁle of patients with different types of AF. The global
study was conducted in 26 countries worldwide, and the
baseline data of the study have been published.17 The total
duration of recruitment was 5 months with six weeks
recruitment phase per country. The study was conducted in
accordance with the Helsinki principles,18 guidelines for
Good Epidemiological Practices,19,20 and local regulations.
The study was approved in the participating centers by the
respective Institutional Ethical Committee. In India, the
clinical operations were managed by Medical Affairs Clinical
Operation unit of Sanoﬁ, India.
2.1. Physician selection
Physicians were selected randomly from a pan-Indian,
extended list of ofﬁce or hospital-based cardiologists. The list
comprised ≥10 times the total number of cardiologists required
Table 1 – Demographics, cardiovascular risk profile, and
symptom history of variables.
Variables Observation
Mean age in years (SD) 59.9 (14.4)
No. of patients above 60 years 176/301 (58.5%)
No. of males 158/301 (52.5%)
Mean body mass index (kg/m2) (SD) 24.5 (4.5)
No. of obese patients 28/289 (9.7%)
Mean systolic blood pressure in
mmHg (SD)
124.7  18.1
Mean diastolic blood pressure in
mmHg (SD)
77.4  10.1
No. of patients with uncontrolled blood
pressurea
109/299 (36.5%)
No. of patients (%) with at least one
symptom
256 (85.0%)
No of patients (%) with at least one
symptom within the past one week
203/256 (89.8%)
Palpitations 112/203 (55%)
Dyspnea 134/203 (66%)
Fatigue 99/203 (48.7%)
Light headedness/dizziness 38/203 (18.7%)
Chest pain 43/203 (21%)
Syncope 9/203 (4.4%)
No. of patients (%) with at least one
cardiovascular event within the
preceding 12 months
92/295 (31.2%)
No. of patients (%) with at least one
cardiovascular intervention within the
preceding 12 months
70/300 (23.3%)
Valve surgery 44/300 (14.6%)
Percutaneous coronary intervention 13/300 (4.3%)
Coronary artery bypass graft 12/300 (4%)
Others 5/300 (1.6%)
SD = standard deviation.
a Controlled blood pressure: for diabetes patients – systolic blood
pressure (SBP) < 130 mmHg or diastolic blood pressure (DBP)
< 80 mmHg, and for non-diabetic patients – SBP < 140 mmHg or
DBP < 90 mmHg.
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accurately reﬂect the practices according to each region.
2.2. Patient selection
Patients meeting the following eligibility criteria were consid-
ered for enrolment in the study.
Inclusion criteria: All consenting patients with documented
current AF or with history of AF in the last 12 months (treated/
not treated and whatever the rhythm at inclusion) were
included in ReleaseAF registry. Patients with history of AF
were qualiﬁed for enrollment if at least one AF episode was
present within the last 12 months, documented by either
standard electrocardigram (ECG) or by Holter monitoring. The
patients or legal representatives (for minors) signed the
written informed consent form approved by the ethics
committee of the respective participating centers.
Exclusion criteria: Mentally disabled patients (including
dementia and signiﬁcant cognitive disorders) unable to
understand or sign the written informed consent, patients
within three months after surgery, and patients participating
concomitantly in a clinical trial in the ﬁeld of AF or in the ﬁeld
of antithrombotic treatment in the previous month were not
included.
The selected physicians included 10 consecutive eligible
patients (maximum of 30 patients) meeting the inclusion and
exclusion criteria. The maximum duration of recruitment per
site was six weeks. Patient information was collected using a
centralized case report form which included baseline character-
istics, symptoms, ECG data, medical history, risk factors, current
medications, history and characteristics of AF, management of
AF in terms of strategy chosen (rate vs. rhythm control),
antiarrhythmic drugs, and/or rate control agents chosen, and
use of antithrombotics (in relation to CHADS2 score). The QoL of
patients was measured using EQ 5-D instrument,21 a standard-
ized instrument for describing health status.
2.3. Statistical analysis
Descriptive statistics for the categorical variables were per-
formed by computing the frequencies (percentages) in each
category. For the quantitative variables, variables following
normal distribution were summarized by mean and standard
deviation (SD) and the remaining as median and range. The
detailed statistical analyses and sample size calculation of the
global RealiseAF study were described elsewhere.17
3. Results
3.1. Demographics and CV risk proﬁle
Between 2nd February 2010 and 31st March 2010, a total of 301
consecutive patients were enrolled in the study from 15
centers across India. Of the total 301 patients, 107 (35.5%) were
inpatients and 194 (64.5%) were outpatients. The mean age
was 59.9 (14.4) years, range 14–89 years. Fifty-three percent
were males. The body mass index systolic and diastolic blood
pressure were 24.5 (4.5) kg/m2 and 124.7 (18.1) and 77.4 (10.1)
mmHg respectively. Eighty-ﬁve percent of patients weresymptomatic with 90% of them having at least one symptom
within the last one week of assessment. Dyspnea was the most
common symptom observed during the previous 12 months
and also within the previous one week, followed by palpita-
tions and fatigue. The demographic and clinical data are
presented in Table 1.
3.2. Cardiovascular events leading to hospitalization
A total of 92 (31.9%) patients with at least one CV event were
admitted to hospitals during the previous 12 months. Acute
decompensated HF was the most common CV event leading to
hospitalization, followed by acute coronary syndrome and
stroke (Fig. 1). Thirty-eight percent of ACS events: 52% of
stroke, 62% of decompensated HF, and 67% of non-neurologi-
cal embolic events occurred after AF was diagnosed.
3.3. Cardiovascular risk factors and risk of stroke
Hypertension was the most common underlying CV condition
(50.8%), followed by VHD (40.7%), HF (25.9%), coronary artery
Fig. 1 – Major cardiovascular events leading to
hospitalization. Abbreviations: ACS, acute coronary
syndrome; HF, heart failure (decompensated); CNS, central
nervous system; TIA, transient ischemic attack.
Table 2 – Cardiovascular risk factors and history of
cardiovascular and non-cardiac co-morbidities.
Variables n (%)
Arterial hypertension, (n = 297) 151 (50.8)
Diabetes mellitus, (n = 299) 61 (20.4)
Valvular heart disease, (n = 300) 122 (40.7)
Mitral 107 (36.4)
Aortic 26 (8.8)
Other 9 (3.1)
Coronary artery disease, (n = 286) 67 (23.4)
Dyslipidemia, (n = 250) 41 (16.4)
Physical inactivity, (n = 301) 153 (50.8)
Family history of AF, (n = 300) 7 (2.3)
History of heart failure, (n = 297) 77 (25.9)
Smoking, (n = 301) (18.6)
Peripheral arterial disease, (n = 292) 6 (2.1)
Past stroke/TIA, (n = 295) 28 (9.5)
CHADS2 score
a, (n = 287)
Missing, n 14
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(Fig. 2). Mitral valve was the most frequently involved valve
(87.7%). The risk of stroke as estimated using CHADS2 score
was ≥2 in 36% of patients. The CV risk factors and history of CV
and non-CV diseases are presented in Table 2.
3.4. Control of atrial ﬁbrillation
One hundred and forty-four of 288 patients (50%) had
controlled AF of whom 77 (53.4%) were in sinus rhythm and
the remaining (46.5%) had HR ≤80 beats/min.Fig. 2 – Major cardiovascular risk factors/diseases in global
and Indian patients in RealiseAF study. Reference: Steg
et al.17 Abbreviations: CAD, coronary artery disease; CV,
cardiovascular; HF, heart failure; VHD, valvular heart
disease.3.5. Atrial ﬁbrillation characteristics
The duration since the ﬁrst diagnosis of AF was 6.5 months
median ranging from 0 to 278 months. Eighty-six (28.6%)
patients had paroxysmal AF, 68 (22.6%) patients had persistent
AF, and 103 (34.3%) patients had permanent AF. In 43 (14.3%)
patients, AF was diagnosed for the ﬁrst time. Table 3 presents
AF characteristics.
3.6. Treatment strategy for atrial ﬁbrillation
Data were available for 293 patients and of these, 135 (46.1%)
received rate control treatment, 103 (35.2%) received rhythm
control treatment, 1 (0.3%) patient received both while 54
(18.4%) patients did not receive any drugs for AF before the
study visit (Fig. 3). At the end of the visit, more patients
received both rate control (157, 52.3%) and rhythm control (106,
35.3%) strategies. After the study visit, there were 16 (5.3%)0 78 (27.2)
1 104 (36.2)
2 61 (21.3)
3 30 (10.5)
4 12 (4.2)
5 2 (0.7)
Patients with at least one co-morbidity, (n = 296) 229 (77.4)
Bradycardia, (n = 297) 16 (5.4)
Atrial ﬂutter (other than 1 to 1), (n = 297) 14 (4.7)
Sick sinus syndrome, (n = 297) 7 (2.4)
Non-cardiovascular diseases
Chronic pulmonary disease, (n = 291) 26 (8.9)
At least 1 thyroid disease, (n = 271) 29 (10.7)
Hypothyroidism 27/271 (9.9)
Hyperthyroidism 2/271 (0.7)
Liver diseases, (n = 292) 12 (4.1)
Chronic advanced liver failure, (n = 296) 9 (3.0)
Malignancies, (n = 289) 4 (1.4)
Abbreviations: AF, atrial ﬁbrillation; BMI, body mass index; NYHA,
New York Heart Association, TIA, transient ischemic attack.
a CHADS2 score: 1 point each for history of heart failure, arterial
hypertension, age > 75 years, history of diabetes, 2 points for
history of stroke or history of TIA.
Table 4 – Antiarrhythmic use on the day of the visit.
Atrial ﬁbrillation treatment n (%) (n = 301)
Patients with at least one AAD 249 (82.7)
Class IC (Flecainide, other) 4 (1.3)
Class II, beta-blockers 116 (38.5)
Class III 118 (39.2)
Amiodarone 112 (37.2)
Sotalol 6 (2.0)
Others 4 (1.3)
Class IV, calcium-channel blockers 75 (24.9)
Cardiac glycosides 96 (31.9)
AAD, antiarrhythmic drug.
Table 3 – Atrial fibrillation characteristics.
Variable Observation
(n = 301)
Lone AFa 24 (8.1)
Time since ﬁrst AF
diagnosis in months,
median (range)
6.5 (0–278)
Missing, n 28
<3 months 113 (41.4)
3–6 months 22 (8.1)
6–12 months 23 (8.4)
>12 months 115 (42.1)
Type of AF
Missing, n 1
First episode 43 (14.3%)
Paroxysmal 86 (28.7%)
Persistent 68 (22.7%)
Permanent 103 (34.3%)
a Patients younger than 60 years of age without clinical or
echocardiographic evidence of any sort of cardiopulmonary
disease, including hypertension.
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21 (7.0%) patients who did not receive any treatment.
3.7. Pharmacologic treatment for AF management
On the day of study visit, Class III drugs (39.2%) was the most
common pharmacologic treatment prescribed, followed by
beta-blockers (38.5%) and cardiac glycosides (31.9%). Class IC
antiarrhythmic drugs (AADs) were prescribed to four
patients, while class IAAADs were not prescribed at all
(Table 4).
3.8. Stroke risk and prevention
As the risk of stroke increased, increasing number of
patients received antiplatelet agent. Among 105 patients
who were at high risk for stroke, 15.2% patients
received both antiplatelet and anticoagulant, 38% received
anticoagulation, and 58% received antiplatelet but no
anticoagulation therapy (Fig. 4).Fig. 3 – Type of therapeutic strategy used for management
of atrial fibrillation.3.9. Quality of life
Majority of the patients had either no problem at all or some to
moderate problem with all the ﬁve aspects of the question-
naire. Severe problems were reported by 8% of patients with
mobility, 9% with self-care, 10% with usual activities, and 5%
each with pain/discomfort and anxiety/depression (Fig. 5).
4. Discussion
The data provided here on the Indian subset data of the global
RealiseAF study reﬂect the real-life scenario of the epidemiol-
ogy of AF in India in terms of patient characteristics, therapies
used to control of AF, and CV risk proﬁle of AF patients.
Our results showed that in 50% of patients, AF was not
adequately controlled and majority of the patients, i.e. 85%
were symptomatic within the previous one year and 90%
within one week. This study illustrates the inadequate control
of AF and the high prevalence of symptoms, among patients
who were being treated for AF.
Earlier studies showed that hypertension, HF, diabetes,
previous stroke/systemic embolism/transient ischemic attack,Fig. 4 – Prescription pattern of antithrombotic agents on the
day of the visit according to CHADS2 score. n = 287. CHADS2
score is calculated as 1 point for 'history of heart failure', 1
point for 'arterial hypertension', 1 point for 'age > 75 years',
1 point for 'history of diabetes', 2 points for 'history of
stroke' or 'history of TIA'.
Fig. 5 – Response to EQ5D questionnaire. X axis shows the five dimensions on the health-related quality of life state and Y
axis the percentage of responses given by the patients. Levels of scoring: 1 = no problem, 2 = some to moderate problems,
3 = severe problem.
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in AF (RELY,23 ARISTOTLE24 and ROCKET AF25) suggest
hypertension as the most prevalent (80–90%) co-morbid
disease. In line with the earlier evidence, in our study also,
the interplay between AF and other CV conditions was evident.
These patients were at high risk of CV events leading to
hospitalization. In the global RealiseAF cohort,17 hypertension
(72.2%), dyslipidemia (46.3%), HF (45.8%), and coronary artery
disease (32.3%) were the most common risk factors. Amongst
the CV disease proﬁle in the Indian sub-study, VHD is
strikingly more prevalent at 41% and the other risk factors
were comparatively less (Fig. 2). However, the present study
did not capture the prevalence of rheumatic VHD in this group.
Many randomized clinical trials such as AFFIRM,26 RACE,27
PIAF,28 STAF,29 AF-CHF,30 and CAFÉ-II31 demonstrate that
there is no signiﬁcant difference between rhythm control and
rate control strategies in terms of overall mortality or stroke
rate. In fact, both these strategies are important and treatment
should be individualized according to the clinical proﬁle of
patients.32 In our study, rate control (52.3%) was the preferred
treatment as compared to rhythm control treatment (35.3%),
while 40.5% of patients used at least one AAD per rhythm
control in management of AF. The preferred treatment
strategies in Indian patients were similar to those in the
global patients.16
International guidelines recommend management of AF
with rate control and/or rhythm control using various
combinations of AADs, and use of anticoagulants, depending
upon the presence of paroxysmal, persistent, or permanent
AF.33,34 Based on the guidelines, AADs are the ﬁrst line
treatment for patients with paroxysmal or persistent AF.
Many AADs including amiodarone, propafenone, ﬂecainide,
and sotalol have been shown to be effective in the prevention
of AF recurrences; however, AADs could have cardiac and
extra-cardiac toxicity (i.e. amiodarone).35 The American
College of Cardiology/American Heart Association/EuropeanSociety of Cardiology (ACC/AHA/ESC) 2006 guidelines also
reﬂect the fact that there are no truly safe and effective
AADs for prevention of AF.34 Non-availability of Class IC
agents in India at the time of the study resulted in excess
use of amiodarone for rhythm control. As a result, 61.5% of
evaluated paroxysmal or persistent AF patients without
congestive HF or hypertension received amiodarone as ﬁrst-
line treatment, despite guidelines recommending that it be
used as a second-line agent. Also, as recommended by the
guidelines, high-risk patients should be given vitamin K
antagonist (VKA),33,36 while in low-risk patients, an anti-
platelet is recommended.33 In our study, only 38% of
patients with high risk received VKA, while 58% of patients
did not receive any anticoagulants. Our results are in line
with earlier reports in other Asian patient populations
which reported underuse of oral anticoagulant therapy.37,38
This underscores the need for simpler and safer antic-
oagulants in AF patients.39
4.1. Limitations of the study
As the ethnic population of India is diverse, a breakdown in
terms of ethnicity and socioeconomic status may
provide insights into factors that may modulate the
compliance/response to pharmacotherapy for AF. However,
the study did not capture information on these variables. The
cross-sectional design of the study makes interpretation
of data such as control of AF and the rationale behind the
choice of management strategies difﬁcult to comprehend.
The sites involved in the study were all in urban areas.
All physicians involved in the study are attached to private
healthcare institutions. The inclusion of study sites
from rural geographical areas and also public healthcare
institutions could have possibly depicted a higher
prevalence of AF and the proportion of patients at risk
of stroke.
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This cross-sectional, observational survey of real-life clinical
practice, demonstrates that AF is not adequately controlled
in India with appropriate choice of antiarrhythmic drugs. A
good proportion of patients who are at high risk for stroke do
not receive anticoagulation. The results highlight the need
for improved antiarrhythmic drugs and antithrombotic
treatments for optimal management of AF.
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